Pacific-Link helps clients find new business development opportunities to expand their business including orphan drug designation and early product development.
PLC has extensive business development experience in Investigational New Drug (IND) strategy and management, New Drug Applications (NDA’s) and New Drug submissions (NDS for Canada) as well as finding compounds with potential transformative value that fit your company’s mission and clinical area of expertise.
Key Offerings for Business Development
PLC’s overall strategy is to find the best fit for your company’s goals. Whether you are a small or medium-sized start-up biotech company looking to IPO or to sell a product, or an established large corporation filling your compound pipeline, PLC can deliver the expertise to evaluate your options and discover collaborative opportunities that create value. Our consultants have decades of experience in pharmaceuticals and understand the diverse and ever changing landscape of laws and regulations governing the United States, Japanese, Canadian and European markets. Our consultants are native to these territories and know how to navigate their systems. Our consultants have extensive connections with companies that operate in these areas that can lead to finding new compounds at various stages of proof of concept or established compounds with new potential clinical designations.
PLC also handles all clinical assessment and trials, including early phase and late stage, regulatory affairs, including IND, NDA/ANDA and PMA’s as well as safety management and analysis.